Abstract
Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C.
Highlights
Previous clinical epidemiological studies have demonstrated an increased risk of B-cell lymphoproliferative disorders in patients with chronic hepatitis C virus (HCV) infection.[1]
Associations with mucosa-associated lymphoid tissue lymphoma, lymphoplasmacytic lymphoma (LPL) and diffuse large B-cell lymphoma (DLBCL) have been reported, an association between HCV and mantle cell lymphoma (MCL) is uncommon.[1]. These observations were substantiated by the EPILYMPH study that identified DLBCL, MZL and LPL as most frequently associated with HCV infection.[2]
The large International Lymphoma Epidemiology Consortium (InterLymph) case–control study quantified the lymphoma risk associated with HCV infection as follows: DLBCL (odds ratio (OR) = 2.24)), MZL (OR = 2.47) and LPL (OR = 2.57).[3]
Summary
Previous clinical epidemiological studies have demonstrated an increased risk of B-cell lymphoproliferative disorders in patients with chronic hepatitis C virus (HCV) infection.[1]. Previous clinical epidemiological studies have demonstrated an increased risk of B-cell lymphoproliferative disorders in patients with chronic hepatitis C virus (HCV) infection.[1] The most common B-cell non-Hodgkin’s lymphoma associated with HCV is marginal zone lymphoma (MZL), including splenic and extranodal (mainly non-gastric) forms.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
